OptiBiotix Health will have its two abstracts presented at ProBiota 2017 in Berlin, which is taking place from February 1-3, 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries.
OptiBiotix’s CEO Stephen o’Hara said that presenting at a major conference like this one will support the launch of a range of cardiovascular products to reduce LDL cholesterol, blood pressure and cardiovascular risk, planned for the spring of 2017. The publications will serve as marketing literature, and provide strong evidence for sales.
The two abstracts will be about OptiBiotix work on cholesterol lowering probiotic. One piece will cover the results of the clinical study. The second will cover the work on species specific microbiome modulators which OptiBiotix has used to enhance the cholesterol reducing effect of their cholesterol reducing strain (LP-LDL). “In the case of this strain, it leads to a threefold increase in the strains ability to lower cholesterol,” the company has explained.